

Supplemental Tables for:  
Health related quality of life in breast cancer patients in Latin America and the Caribbean: a systematic review and meta-analysis  
Lucas Angel Damian Gonzalez et al.

S1. Search strategy for literature review used and date of its implementation.

- **PUBMED (14-08-2018)**

Search	Query	Items found
#85	Search (#69 AND #82 AND #83) Filters: Publication date from 2003/01/01	1377
#84	Search (#69 AND #82 AND #83)	1732
#83	Search (Americas[MeSH Terms:noexp] OR America*[tiab] OR Latin America[Mesh] OR Latin America*[tiab] OR Latinamerica*[tiab] OR Latinoamerica*[tiab] OR Latin*[tiab] OR Hispanic Americans[Mesh] OR Hispanic America*[tiab] OR Hispanoamerica*[tiab] OR Iberoamerica*[tiab] OR Ibero Americ*[tiab] OR Panamerican*[tiab] OR Central America[Mesh] OR Central America*[tiab] OR Centroamerica*[tiab] OR Mesoamerica*[tiab] OR Meso America*[tiab] OR Middle America*[tiab] OR South America[Mesh] OR South America*[tiab] OR Southamerica*[tiab] OR Sudamerica*[tiab] OR "America del sur"[tiab] OR Caribbean Region[Mesh] OR Caribbean[tiab] OR Caribe*[tiab] OR West Indies[Mesh] OR West Indi*[tiab] OR Antill*[tiab] OR Indians, South American[Mesh] OR Indians, Central American[Mesh] OR Amerindian*[tiab] OR Indians[tiab] OR American Indian*[tiab] OR Native America*[tiab] OR Patagoni*[tiab] OR Andes[tiab] OR Andean*[tiab] OR Amazon*[tiab] OR Argentin*[ad] OR Argentin*[tiab] OR Argentina[pl] OR Bolivia*[ad] OR Bolivia*[tiab] OR Bolivia[pl] OR Brazil*[ad] OR Brasil*[ad] OR Brazil*[tiab] OR Brasil*[tiab] OR Brazil[pl] OR Colombia*[ad] OR Colombia*[tiab] OR Colombia[pl] OR Chile*[ad] OR Chile*[tiab] OR Chile[pl] OR Ecuador*[ad] OR Ecuador*[ad] OR Ecuador*[tiab] OR Ecuador[pl] OR Guiana*[ad] OR Guiana*[tiab] OR French Guiana[pl] OR Guyan*[ad] OR Guyan*[tiab] OR Guyana[pl] OR Paraguay*[ad] OR Paraguay*[tiab] OR Paraguay[pl] OR Peru*[ad] OR Peru*[tiab] OR	1298120

Search	Query	Items found
	Peru[pl] OR Surinam*[ad] OR Surinam*[tiab] OR Suriname[pl] OR Uruguay*[ad] OR Uruguay*[tiab] OR Uruguay[pl] OR Venez*[ad] OR Venez*[tiab] OR Venezuela[pl] OR Belize*[ad] OR Belize*[tiab] OR Belize[pl] OR Costa Ric*[ad] OR Costarric*[ad] OR Costaric*[ad] OR Costa Ric*[tiab] OR Costarric*[tiab] OR Costaric*[tiab] OR Costa Rica[pl] OR Salvador*[ad] OR Salvador*[tiab] OR El Salvador[pl] OR Guatemal*[ad] OR Guatemal*[tiab] OR Guatemala[pl] OR Hondur*[ad] OR Hondur*[tiab] OR Honduras[pl] OR Nicaragu*[ad] OR Nicaragu*[tiab] OR Nicaragua[pl] OR Panam*[ad] OR Panam*[tiab] OR Panama[pl] OR Mexico[Mesh] OR Mexic*[ad] OR Mexic*[tiab] OR Mejjc*[tiab] OR Mexico[pl] OR Cuba*[ad] OR Cuba*[tiab] OR Cuba[pl] OR OR Dominic*[ad] OR Dominic*[tiab] OR Dominican Republic[pl] OR Haiti*[ad] OR Haiti*[tiab] OR Haiti[pl] OR Jamaic*[ad] OR Jamaic*[tiab] OR Jamaica[pl] OR Puerto Ric*[tiab] OR Puertoric*[tiab] OR Puertoric*[tiab])	
#82	Search (#70 OR #71 OR #72 OR #73 OR #74 OR #75 OR #76 OR #77 OR #78 OR #79 OR #80 OR #81)	349456
#81	Search Breast Malignan*[tiab]	1093
#80	Search Breast Neoplas*[tiab]	9327
#79	Search Breast Carcinom*[tiab]	28709
#78	Search Breast Cancer[tiab]	238494
#77	Search Breast Tumors[tiab]	10345
#76	Search Breast Tumor[tiab]	8769
#75	Search Mammary Carcinom*[tiab]	7973

Search	Query	Items found
#74	Search Mammary Tumors[tiab]	5646
#73	Search Mammary Tumor[tiab]	7956
#72	Search Mammary Cancer[tiab]	3006
#71	Search Mammary Neoplas*[tiab]	885
#70	Search Breast Neoplasms[Mesh]	266019
#69	Search (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42 OR #43 OR #44 OR #45 OR #46 OR #47 OR #48 OR #49 OR #50 OR #51 OR #52 OR #53 OR #54 OR #55 OR #56 OR #57 OR #58 OR #59 OR #60 OR #61 OR #62 OR #63 OR #64 OR #65 OR #66 OR #67 OR #68)	1147004
#68	Search Diagnostic Pattern*[tiab]	490
#67	Search Treatment Pattern*[tiab]	3376
#66	Search Prescribing Pattern*[tiab]	2605
#65	Search Practice Pattern*[tiab]	7361
#64	Search Practice Patterns, Physicians[Mesh]	52872
#63	Search Utilization Rate*[tiab]	3646

Search	Query	Items found
#62	Search Usage[tiab]	80840
#61	Search Resource Use[tiab]	7250
#60	Search Health Resource*[tiab]	5189
#59	Search Health Resources[Mesh]	23503
#58	Search Lost Productivity[tiab]	1132
#57	Search VOLP[tiab]	7
#56	Search Stanford Presenteeism[tiab]	43
#55	Search Work Questionnaire[tiab]	63
#54	Search HWQ[tiab]	4
#53	Search Work Performance*[tiab]	2050
#52	Search WHO-HPQ[tiab]	4
#51	Search Work Limitat*[tiab]	332
#50	Search WLQ[tiab]	79
#49	Search Work Productivity[tiab]	1461

Search	Query	Items found
#48	Search WPAL[tiab]	263
#47	Search Medical Saving*[tiab]	184
#46	Search Coinsurance*[tiab]	277
#45	Search Deductible*[tiab]	824
#44	Search Visual-Analog Scale*[tiab]	22573
#43	Search Health Utilit*[tiab]	1725
#42	Search Standard Gamble[tiab]	795
#41	Search Time-Trade Off[tiab]	1048
#40	Search QALY*[tiab]	8687
#39	Search Conjoint Analysis[tiab]	649
#38	Search "Willingness to Pay"[tiab]	4369
#37	Search Contingent Valuat*[tiab]	626
#36	Search Pricing[tiab]	4622
#35	Search Price*[tiab]	32086

Search	Query	Items found
#34	Search Pharmacoeconomic*[tiab]	3635
#33	Search Economic*[ti]	41874
#32	Search Costly[tiab]	30605
#31	Search Costed[tiab]	296
#30	Search Costs[tiab]	183757
#29	Search Cost[tiab]	362717
#28	Search Disease Burden[tiab]	10880
#27	Search "Burden of Disease"[tiab]	7598
#26	Search ("Costs and Cost Analysis"[Mesh])	217339
#25	Search Budgets[Mesh]	13337
#24	Search ("Fees and Charges"[Mesh])	29359
#23	Search Economics, Nursing[Mesh]	3981
#22	Search Economics, Pharmaceutical[Mesh]	2793
#21	Search Economics, Medical[Mesh]	14037

Search	Query	Items found
#20	Search Economics, Hospital[Mesh]	23014
#19	Search HFRDIS[tiab]	11
#18	Search QLICP*[tiab]	17
#17	Search LSQ-32[tiab]	2
#16	Search FACT-ES[tiab]	24
#15	Search FACT-B[tiab]	231
#14	Search EORTC[tiab]	7129
#13	Search QLQ-C15[tiab]	3
#12	Search QLQ-BR23[tiab]	202
#11	Search QLQ-C30[tiab]	3243
#10	Search EuroQoL[tiab]	4299
#9	Search EQ5D[tiab]	440
#8	Search SF-36[tiab]	18131
#7	Search HRQoL[tiab]	13296

Search	Query	Items found
#6	Search Health-Related Quality[tiab]	36658
#5	Search QoL[tiab]	31624
#4	Search "Quality of Life"[tiab]	225886
#3	Search Health Status[tiab]	50997
#2	Search Life Quality[tiab]	5653
#1	Search Quality of Life[Mesh]	164999

- **EMBASE (ELSEVIER) 21-08-2018**

No.	Query	Results
#113	#64 AND #75 AND #112	941
#112	#76 OR #77 OR #78 OR #79 OR #80 OR #81 OR #82 OR #83 OR #84 OR #85 OR #86 OR #87 OR #88 OR #89 OR #90 OR #91 OR #92 OR #93 OR #94 OR #95 OR #96 OR #97 OR #98 OR #99 OR #100 OR #101 OR #102 OR #103 OR #104 OR #105 OR #106 OR #107 OR #108 OR #109 OR #110 OR #111	437388



No.	Query	Results
#111	'puerto rico'/exp OR 'puerto rico':ab,ti OR puertoric*:ab,ti OR puertorric*:ab,ti OR 'puerto rican':ab,ti	10534
#110	'jamaica'/exp OR jamaic*:ab,ti	5633
#109	'haiti'/exp OR haiti*:ab,ti	5001
#108	'dominican republic'/exp OR dominica*:ab,ti	3646
#107	'cuba'/exp OR cuba*:ab,ti	10291
#106	'mexico'/exp OR mexic*:ab,ti OR mejic*:ab,ti	76085
#105	'panama'/exp OR panam*:ab,ti	5409
#104	'nicaragua'/exp OR nicaragu*:ab,ti	2550
#103	'honduras'/exp OR hondur*:ab,ti	2262
#102	'guatemala'/exp OR guatemal*:ab,ti	4968
#101	'el salvador'/exp OR salvador*:ab,ti	4143
#100	'costa rica'/exp OR 'costa rica':ab,ti OR costarric*:ab,ti OR costaric*:ab,ti OR 'costa rican':ab,ti	5865
#99	'belize'/exp OR beliz*:ab,ti	985
#98	'venezuela'/exp OR venez*:ab,ti	11298

No.	Query	Results
#97	'uruguay'/exp OR uruguay*:ab,ti	3794
#96	'suriname'/exp OR surinam*:ab,ti	1885
#95	'peru'/exp OR peru*:ab,ti	17882
#94	'paraguay'/exp OR paraguay*:ab,ti	2044
#93	'guyana'/exp OR guyan*:ab,ti	1831
#92	'french guiana'/exp OR guiana*:ab,ti	1780
#91	'ecuador'/exp OR ecuador*:ab,ti	5948
#90	'ecuador'/exp OR ecuador*:ab,ti	5948
#89	'chile'/exp OR chile*:ab,ti	21519
#88	'colombia'/exp OR colombia*:ab,ti	20485
#87	'brazil'/exp OR brazil*:ab,ti OR brasil*:ab,ti	146812
#86	'bolivia'/exp OR bolivia*:ab,ti	4664
#85	'argentina'/exp OR argentin*:ab,ti	27479
#84	amerindian*:ab,ti OR indians:ab,ti OR 'american indians':ab,ti OR 'native american':ab,ti OR patagoni*:ab,ti OR andes:ab,ti OR andean*:ab,ti OR amazon*:ab,ti	38229

No.	Query	Results
#83	'american indian'/exp	17024
#82	'caribbean islands'/exp	28812
#81	caribbean*:ab,ti OR caribe*:ab,ti OR 'west indies':ab,ti OR antill*:ab,ti	18201
#80	'caribbean'/exp	2076
#79	'south america':ab,ti OR southamerica*:ab,ti OR sudamerica*:ab,ti OR 'america del sur':ab,ti OR 'central america':ab,ti OR centroamerica*:ab,ti OR mesoamerica*:ab,ti OR 'meso america':ab,ti OR 'middle america':ab,ti	18718
#78	'latin america':ab,ti OR 'latin america':ti,ab OR latinamerica*:ab,ti OR latinoamerica*:ab,ti OR hispanoamerica:ab,ti OR iberoamerica*:ab,ti OR 'ibero america':ab,ti OR panamerican*:ab,ti	16982
#77	'south and central america'/exp	204827
#76	americas:ab,ti	6980
#75	#65 OR #66 OR #67 OR #68 OR #69 OR #70 OR #71 OR #72 OR #73 OR #74	534178
#74	'breast malignancy':ti,ab OR 'breast malignancies':ti,ab	1506
#73	'breast neoplasm':ti,ab OR 'breast neoplasms':ti,ab	1156
#72	'breast carcinoma':ti,ab OR 'breast carcinomas':ti,ab	36644
#71	'breast cancer':ti,ab	336554

No.	Query	Results
#70	'breast tumor':ti,ab OR 'breast tumors':ti,ab	24064
#69	'mammary carcinoma':ti,ab OR 'mammary carcinomas':ti,ab	9918
#68	'mammary tumor':ti,ab OR 'mammary tumors':ti,ab	14129
#67	'mammary cancer':ti,ab	3794
#66	'mammary neoplasm':ti,ab OR 'mammary neoplasms':ti,ab	252
#65	'breast tumor'/exp	490468
#64	#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42 OR #43 OR #44 OR #45 OR #46 OR #47 OR #48 OR #49 OR #50 OR #51 OR #52 OR #53 OR #54 OR #55 OR #56 OR #57 OR #58 OR #59 OR #60 OR #61 OR #62 OR #63	2053279
#63	'diagnostic pattern':ti,ab OR 'diagnostic patterns':ti,ab	652
#62	'treatment pattern':ti,ab OR 'treatment patterns':ti,ab	7301
#61	'prescribing pattern':ti,ab OR 'prescribing patterns':ti,ab	4323
#60	'practice pattern':ti,ab OR 'practice patterns':ti,ab	10589
#59	'clinical practice'/exp	242395

No.	Query	Results
#58	'utilization rate':ti,ab	2474
#57	usage:ti,ab	108439
#56	'resource use':ti,ab	10571
#55	'health resources':ti,ab	4931
#54	'lost productivity':ti,ab	1630
#53	volp:ti,ab	13
#52	'stanford presenteeism':ti,ab	47
#51	'work questionnaire':ti,ab	90
#50	hwq:ti,ab	6
#49	'work performance':ti,ab	2666
#48	'who hpq':ti,ab	10
#47	'work limitation':ti,ab	127
#46	wlq:ti,ab	156
#45	'work productivity':ti,ab	3204

No.	Query	Results
#44	wpai:ti,ab	1173
#43	'medical saving':ti,ab OR 'medical savings':ti,ab	219
#42	coinsurance*:ti,ab	391
#41	deductible*:ti,ab	1046
#40	'visual analog scale':ti,ab	26680
#39	'health utilities':ti,ab OR 'health utility':ti,ab	2725
#38	'standard gamble':ti,ab	1002
#37	'time trade off':ti,ab	1477
#36	qaly*:ti,ab	15786
#35	'conjoint analysis':ti,ab	794
#34	'willingness to pay':ti,ab	6599
#33	'contingent valuation':ti,ab	754
#32	pricing:ti,ab	6710
#31	price*:ti,ab	44709

No.	Query	Results
#30	pharmacoeconomic*:ti,ab	7341
#29	economic*:ti	53320
#28	costly:ti,ab	40693
#27	costed:ti,ab	470
#26	costs:ti,ab	255341
#25	cost:ti,ab	475818
#24	'disease burden':ti,ab	16623
#23	'disease burden'/exp	26766
#22	'cost'/exp	321996
#21	'budget'/exp	25541
#20	'health economics'/exp	779220
#19	hfrdis:ti,ab	28
#18	qlicp*:ti,ab	27
#17	'lsq-32':ti,ab	2

No.	Query	Results
#16	'fact-es':ti,ab	74
#15	'fact-b':ti,ab	533
#14	eortc:ti,ab	14557
#13	'qlq c15':ti,ab	184
#12	'qlq br23':ti,ab	374
#11	'qlq c30':ti,ab	6308
#10	euroqol:ti,ab	6384
#9	eq5d:ti,ab	1387
#8	'sf 36':ti,ab	29105
#7	hrqol:ti,ab	20979
#6	'health related quality':ti,ab	50857
#5	qol:ti,ab	59077
#4	'quality of life':ti,ab	345484
#3	'health status':ti,ab	63091



No.	Query	Results
#2	'life quality':ti,ab	10858
#1	'quality of life'/exp	424958

- **LILACS (BVS-ENGLISH) 23 -08-2018**

Database :	LILACS
Search on :	MH Breast Neoplasm AND (MH Quality of Life OR MH Economics, Hospital OR MH Economics, Medical OR MH Economics, Pharmaceutical OR MH Economics, Nursing OR MH “Fees and Charges” OR MH Budgets OR MH “Costs and Cost Analysis” OR ((productividad OR productivity OR Produtividade) AND (loss OR perdida OR perda) AND (work OR laboral OR trabajo OR trabalho)) OR WPAI OR WHO-HPQ OR Presenteeism OR Presentismo OR Presenteismo OR ((Resource\$ OR Recursos) AND (Uso OR Use))) [Words]
References found :	175 [refine]

- **ECONLIT (EBSCO) 23-08-2018**

#	Query	Results
S68	S66 AND S67	4

S67	TI ( Latin America* OR Latinamerica* OR Latinoamerica* OR Latin* OR Hispanic Americans OR Hispanic America* OR Hispanoamerica* OR Hispano* OR Hispanic* OR Iberoamerica* OR Ibero Americ* OR Panamerican* OR Central America* OR Centroamerica* OR Mesoamerica* OR Meso America* OR Middle America* OR South America* OR Southamerica* OR Sudamerica* OR America del sur OR Caribbean OR Caribe* OR West Indi* OR Antill* OR Amerindian* OR Indians OR American Indian* OR Native America* OR Patagoni* OR Andes OR Andean* OR Amazon* OR Argentin* OR Bolivia* OR Brazil* OR Brasil* Colombia* OR Colombia* OR Colombia OR Chile* OR Ecuador* OR Guiana* OR Guyan* OR Guyan* OR Paraguay* OR Paraguay* OR Peru* OR Surinam* OR Surinam* OR Uruguay* OR Venez* OR Belize* OR Costa Ric* OR Costarric* OR Costaric* OR Costa Ric* OR Costarric* OR Salvador* OR Salvador* OR El Salvador OR Guatemal* OR Guatemal* OR Guatemala OR Hondur* OR Nicaragu* Panam* OR Mexic* OR Cuba* OR Dominic* OR Dominic* OR Haiti* OR Jamaic* OR Puerto Ric* OR Puertoric* OR Puertoric* ) OR AB ( Latin America* OR Latinamerica* OR Latinoamerica* OR Latin* OR Hispanic Americans OR Hispanic America* OR Hispanoamerica* OR Hispano* OR Hispanic* OR Iberoamerica* OR Ibero Americ* OR Panamerican* OR Central America* OR Centroamerica* OR Mesoamerica* OR Meso America* OR Middle America* OR South America* OR Southamerica* OR Sudamerica* OR America del sur OR Caribbean OR Caribe* OR West Indi* OR Antill* OR Amerindian* OR Indians OR American Indian* OR Native America* OR Patagoni* OR Andes OR Andean* OR Amazon* OR Argentin* OR Bolivia* OR Brazil* OR Brasil* Colombia* OR Colombia* OR Colombia OR Chile* OR Ecuador* OR Guiana* OR Guyan* OR Guyan* OR Paraguay* OR Paraguay* OR Peru* OR Surinam* OR Surinam* OR Uruguay* OR Venez* OR Belize* OR Costa Ric* OR Costarric* OR Costaric* OR Costa Ric* OR Costarric* OR Salvador* OR Salvador* OR El Salvador OR Guatemal* OR Guatemal* OR Guatemala OR Hondur* OR Nicaragu* Panam* OR Mexic* OR Cuba* OR Dominic* OR Dominic* OR Haiti* OR Jamaic* OR Puerto Ric* OR Puertoric* OR Puertoric* )	75,822
S66	S55 AND S65	134
S65	S56 OR S57 OR S58 OR S59 OR S60 OR S61 OR S62 OR S63 OR S64	297
S64	TI Breast Malignan* OR AB Breast Malignan*	4
S63	TI Breast Neoplas* OR AB Breast Neoplas*	1
S62	TI Breast Carcinom* OR AB Breast Carcinom*	6
S61	TI Breast Cancer OR AB Breast Cancer	296

S60	TI Breast Tumor* OR AB Breast Tumor*	12
S59	TI Mammary Carcinom* OR AB Mammary Carcinom*	0
S58	TI Mammary Tumor* OR AB Mammary Tumor*	1
S57	TI Mammary Cancer OR AB Mammary Cancer	0
S56	TI Mammary Neoplas* OR AB Mammary Neoplas*	0
S55	S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24 OR S25 OR S26 OR S27 OR S28 OR S29 OR S30 OR S31 OR S32 OR S33 OR S34 OR S35 OR S36 OR S37 OR S38 OR S39 OR S40 OR S41 OR S42 OR S43 OR S44 OR S45 OR S46 OR S47 OR S48 OR S49 OR S50 OR S51 OR S52 OR S53 OR S54	413,296
S54	TI Treatment Pattern* OR AB Treatment Pattern*	699
S53	TI Prescribing Pattern* OR AB Prescribing Pattern*	28
S52	TI Practice Pattern* OR AB Practice Pattern*	1,538
S51	TI Usage OR AB Usage	4,878
S50	TI Resource Use OR AB Resource Use	12,024
S49	TI Health Resource* OR AB Health Resource*	3,492
S48	TI Lost Productivity OR AB Lost Productivity	275
S47	TI VOLP OR AB VOLP	1
S46	TI Stanford Presenteeism OR AB Stanford Presenteeism	0
S45	TI Work Questionnaire OR AB Work Questionnaire	837

S44	TI HWQ OR AB HWQ	0
S43	TI Work Performance OR AB Work Performance	5,672
S42	TI WHO-HPQ OR AB WHO-HPQ	0
S41	TI Work Limitat* OR AB Work Limitat*	1,041
S40	TI Work Productivity OR AB Work Productivity	3,448
S39	TI WPAI OR AB WPAI	2
S38	TI Medical Saving* OR AB Medical Saving*	382
S37	TI Coinsurance* OR AB Coinsurance*	191
S36	TI Deductible* OR AB Deductible*	582
S35	TI Visual Analog Scale OR AB Visual Analog Scale	52
S34	TI Health Utilit* OR AB Health Utilit*	1,180
S33	TI Standard Gamble OR AB Standard Gamble	120
S32	TI Time Trade Off OR AB Time Trade Off	1,840
S31	TI QALY* OR AB QALY*	428
S30	TI Conjoint Analysis OR AB Conjoint Analysis	528
S29	TI Willingness to Pay OR AB Willingness to Pay	5,333
S28	TI Contingent Valuat* OR AB Contingent Valuat*	2,564
S27	TI ( Price OR Prices ) OR AB ( Price OR Prices )	138,874

S26	TI Pharmacoeconomic* OR AB Pharmacoeconomic*	243
S25	TI Economic*	130,932
S24	TI Costly OR AB Costly	9,179
S23	TI Costed OR AB Costed	16
S22	TI ( Cost OR Costs ) OR AB ( Cost OR Costs )	130,521
S21	TI Disease Burden OR AB Disease Burden	393
S20	TI Burden of Disease OR AB Burden of Disease	393
S19	TI Budget* OR AB Budget*	21,951
S18	TI HFRDIS OR AB HFRDIS	0
S17	TI QLICP* OR AB QLICP*	0
S16	TI LSQ-32 OR AB LSQ-32	0
S15	TI FACT-ES OR AB FACT-ES	0
S14	TI FACT-B OR AB FACT-B	2
S13	TI EORTC OR AB EORTC	1
S12	TI QLQ-C15 OR AB QLQ-C15	0
S11	TI QLQ-BR23 OR AB QLQ-BR23	0
S10	TI QLQ-C30 OR AB QLQ-C30	1
S9	TI EuroQoL OR AB EuroQoL	46

S8	TI EQ5D OR AB EQ5D	147
S7	TI SF-36 OR AB SF-36	41
S6	TI HRQoL OR AB HRQoL	46
S5	TI Health Related Quality OR AB Health Related Quality	724
S4	TI QoL OR AB QoL	165
S3	TI Quality of Life OR AB Quality of Life	5,119
S2	TI Health Status OR AB Health Status	4,396
S1	TI Life Quality OR AB Life Quality	5,119

- **CRD (YORK) 28-08-2018**

Line	Search	Hits
1	(MeSH DESCRIPTOR Quality of Life EXPLODE ALL TREES)	2724
2	(Life Quality )	487
3	(Health Status )	1083
4	(Quality of Life)	8662

5	(QoL )	380
6	(Health-Related Quality)	1026
7	(HRQoL )	151
8	(SF-36 )	347
9	(EQ5D )	14
10	(EuroQoL )	253
11	(QLQ-C30 )	33
12	(QLQ-BR23 )	0
13	(QLQ-C15 )	0
14	(EORTC )	66
15	(FACT-B )	4
16	(FACT-ES )	0
17	(LSQ-32 )	0
18	(QLICP*)	0

19	(HFRDIS )	0
20	MeSH DESCRIPTOR Economics, Hospital EXPLODE ALL TREES	1247
21	MeSH DESCRIPTOR Economics, Medical EXPLODE ALL TREES	53
22	MeSH DESCRIPTOR Economics, Pharmaceutical EXPLODE ALL TREES	199
23	MeSH DESCRIPTOR Economics, Nursing EXPLODE ALL TREES	9
24	MeSH DESCRIPTOR Fees and Charges EXPLODE ALL TREES	290
25	MeSH DESCRIPTOR Budgets EXPLODE ALL TREES	54
26	MeSH DESCRIPTOR Costs and Cost Analysis EXPLODE ALL TREES	17164
27	(Burden of Disease)	130
28	(Disease Burden )	51
29	(Cost OR Costs OR Costed OR Costly)	24118
30	(Economic*):TI	3274
31	(Pharmacoeconomic*)	1016
32	(Price* OR Pricing)	9442



33	(Contingent Valuat* )	8
34	(Willingness to Pay)	923
35	(Conjoint Analysis )	6
36	(QALY*)	3263
37	(Time Trade Off )	368
38	(Standard Gamble )	203
39	(Health Utilit* )	300
40	(Visual Analog Scale)	56
41	(Deductible*)	8
42	(Coinsurance*)	7
43	(Medical Saving* )	6
44	(WPAI )	1
45	(Work Productivity)	28
46	(WLQ)	1

47	(Work Limitat* )	3
48	(WHO-HPQ )	0
49	(Work Performance*)	8
50	(HWQ )	0
51	(Work Questionnaire )	0
52	(Stanford Presenteeism )	0
53	(VOLP )	1
54	(Lost Productivity )	297
55	MeSH DESCRIPTOR Health Resources EXPLODE ALL TREES	287
56	(Health Resource*)	424
57	(Resource Use )	5987
58	(Usage)	507
59	(Utilization Rate*)	5
60	MeSH DESCRIPTOR Practice Patterns, Physicians' EXPLODE ALL TREES	258

61	(Practice Pattern* )	341
62	(Prescribing Pattern*)	34
63	(Treatment Pattern* )	260
64	(Diagnostic Pattern*)	7
65	#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42 OR #43 OR #44 OR #45 OR #46 OR #47 OR #48 OR #49 OR #50 OR #51 OR #52 OR #53 OR #54 OR #55 OR #56 OR #57 OR #58 OR #59 OR #60 OR #61 OR #62 OR #63 OR #64	28698
66	MeSH DESCRIPTOR Breast Neoplasms EXPLODE ALL TREES	1798
67	(Mammary Neoplas*)	0
68	(Mammary Cancer )	0
69	(Mammary Tumor)	0
70	(Mammary Tumors)	0
71	(Mammary Carcinom*)	2
72	(Breast Tumor*)	16

73	(Breast Cancer )	2038
74	(Breast Carcinom* )	39
75	(Breast Neoplas*)	1906
76	(Breast Malignan*)	3
77	#66 OR #67 OR #68 OR #69 OR #70 OR #71 OR #72 OR #73 OR #74 OR #75 OR #76	2360
78	#65 AND #77	1030
79	(Latin America* OR Latinamerica* OR Latinoamerica* OR Latin* OR Hispanic Americans OR Hispanic America* OR Hispanoamerica* OR Hispano* OR Hispanic* OR Iberoamerica* OR Ibero Americ* OR Panamerican* OR Central America* OR Centroamerica* OR Mesoamerica* OR Meso America* OR Middle America* OR South America* OR Southamerica* OR Sudamerica* OR America del sur OR Caribbean OR Caribe* OR West Indi* OR Antill* OR Amerindian* OR Indians OR American Indian* OR Native America* OR Patagoni* OR Andes OR Andean* OR Amazon* OR Argentin* OR Bolivia* OR Brazil* OR Brasil* OR Colombia* OR Colombia* OR Colombia OR Chile* OR Ecuador* OR Guiana* OR Guyan* OR Guyan* OR Paraguay* OR Paraguay* OR Peru* OR Surinam* OR Surinam* OR Uruguay* OR Venez* OR Belize* OR Costa Ric* OR Costarric* OR Costaric* OR Costa Ric* OR Costarric* OR Salvador* OR Salvador* OR El Salvador OR Guatemal* OR Guatemal* OR Guatemala OR Hondur* OR Nicaragu* OR Panam* OR Mexic* OR Cuba* OR Dominic* OR Dominic* OR Haiti* OR Jamaic* OR Puerto Ric* OR Puertorric* OR Puertoric*)	1521
80	MeSH DESCRIPTOR Latin America EXPLODE ALL TREES	26
81	MeSH DESCRIPTOR Central America EXPLODE ALL TREES	14
82	MeSH DESCRIPTOR South America EXPLODE ALL TREES	214

83	MeSH DESCRIPTOR Caribbean Region EXPLODE ALL TREES	35
84	MeSH DESCRIPTOR West Indies EXPLODE ALL TREES	24
85	MeSH DESCRIPTOR Indians, South American EXPLODE ALL TREES	0
86	MeSH DESCRIPTOR Indians, Central American EXPLODE ALL TREES	0
87	#79 OR #80 OR #81 OR #82 OR #83 OR #84 OR #85 OR #86	1531
88	#78 AND #87	23

## S2. Quality assessment tool

Criteria list for assessing the methodological quality of studies on quality of life.

Positive if:

1. Socio-demographic and medical data is described (e.g., age, race, employment status, educational status, tumour stage at diagnosis etc.).
2. Inclusion and/or exclusion criteria are formulated.
3. The process of data collection is described (e.g., interview or self-report etc.).
4. The type of cancer treatment is described.
5. Participation and response rates for patient groups have to be described and have to be more than 75%.
6. A standardized or valid quality of life questionnaire is used.
7. The mean, median, standard deviations or percentages reported for the most important outcomes.
8. All domains of questionnaire are reported.
9. Patient signed an informed consent form before study participation.
10. The degree of selection of the patient sample is described.

Each item was assigned one point. If an item did not meet our criteria or was described insufficiently or not at all, zero points were assigned. The highest possible score was thus 10. Studies scoring 75% or more of the maximum attainable score were arbitrarily considered to be of high quality. Studies scoring between 50% and 75% were rated as moderate quality. Studies scoring lower than 50% were considered low quality.

S3.

Domains of different instruments by Country and stage

SF36

Table A. Meta-analysis of HRQoL by SF-36 broken down by country and stage.							
Stage	I-II and III						IV
Country	Argentina	Brazil	Colombia	Mexico	Peru	Uruguay	Colombia
Studies	1	11	1	2	2	1	1
N	221	897	35	199	153	116	4
Physical Functioning	84 (83.9 - 84.1)	70.2 (66.1 - 74.3)	42.9 (34.8 - 50.9)	72.6 (56.9 - 88.2)	66.7 (54.1 - 79.2)	74 (71.8 - 76.2)	20.8 (8.3 - 33.3)
Role Physical	77.5 (77.3 - 77.7)	48 (36.5 - 59.5)	28 (13.9 - 42)	52.4 (44.3 - 60.4)	53.9 (15 - 92.8)	66.8 (62.2 - 71.4)	12.5 (0 - 37)
Bodily Pain	78 (77.9 - 78.1)	58 (52.4 - 63.5)	30.5 (20.1 - 40.9)	70.1 (58 - 82.3)	73.2 (68 - 78.5)	63 (58.8 - 67.2)	38.6 (3.5 - 73.7)
General Health	74 (73.9 - 74.1)	70 (66.4 - 73.6)	58.5 (48.8 - 68.2)	62.1 (53.8 - 70.3)	65.5 (62.5 - 68.6)	58 (54.4 - 61.5)	38.7 (11.5 - 65.9)
Vitality	60 (59.9 - 60.1)	64 (60.9 - 67.2)	55.8 (47.7 - 63.9)	66.2 (55.7 - 76.8)	75.6 (63.7 - 87.6)	54.7 (51.7 - 57.7)	39.5 (6.7 - 72.3)
Social Functioning	85.5 (85.3 - 85.7)	78.4 (72.3 - 84.4)	38.1 (32.5 - 43.6)	75.6 (64.7 - 86.5)	72.4 (65.5 - 79.4)	70.7 (65.4 - 76)	45 (40.6 - 49.4)
Role Emotional	77 (76.8 - 77.2)	66.8 (52.3 - 81.2)	40.7 (33.7 - 47.8)	56.9 (48 - 65.7)	68.8 (62.4 - 75.2)	67.6 (63.1 - 72.1)	20.8 (0 - 45.3)
Mental Health	74 (73.8 - 74.2)	70.2 (67.2 - 73.2)	60.8 (52 - 69.7)	66.6 (59.7 - 73.4)	71 (64.9 - 77)	48.4 (44.7 - 52)	45 (14.3 - 75.7)

QLQ-C30



**Table B. Meta-analysis of HRQoL by EORTC QLQ-C30 broken down by country and stage.**

Stage	I-II and III								IV	
Country	Argentina	Brazil	Chile	Colombia	Ecuador	Mexico	Paraguay	Peru	Brazil	Mexico
Studies	3	13	2	2	1	5	1	1	2	1
N	343	2245	123	457	40	782	125	76	248	47
Global health status / QoL	69.8 (56.9 - 82.6)	70.1 (65.9 - 74.4)	72.5 (68.7 - 76.2)	74.8 (70.4 - 79.3)	62.5 (59.3 - 65.7)	73.7 (69.8 - 77.6)	60.7 (57.7 - 63.7)	77.1 (72.3 - 81.9)	64.5 (54.8 - 74.2)	66.5 (59.5 - 73.4)
<b>Functional scales</b>										
Physical functioning	78.4 (63.8 - 93)	75.9 (72.9 - 78.8)	89.4 (87.3 - 91.5)	87.8 (86.6 - 89)	87 (82.9 - 91.1)	76.6 (60.5 - 92.7)	85.3 (82 - 88.6)	38.9 (34.9 - 42.9)	64.5 (59.4 - 69.7)	77 (74.7 - 79.3)
Role functioning	77.2 (60.3 - 94)	70.3 (63.4 - 77.1)	86.4(78.7 - 94)	87.6 (84.2 - 91)	91.3 (85.3 - 97.2)	71.4 (61.1 - 81.7)	NR	33.1 (29.1 - 37.1)	53.6 (32.8 - 74.5)	66.9 (57 - 76.7)
Emotional functioning	62.6 (41.2 - 84)	61.1 (57.9 - 64.3)	71.1(67 - 75.2)	79.3(75.3 - 83.2)	66.3(59.8 - 72.7)	66.2 (57.2 - 75.2)	71.2 (66.9 - 75.5)	49.3 (43 - 55.6)	56.8 (51.4 - 62.2)	60.9 (53 - 68.8)
Cognitive functioning	81.1 (73.2 - 89)	69.7 (66.7 - 72.6)	85.6(81.8 - 89.4)	86.4(84.7 - 88)	82.9(78.8 - 87)	75.3 (60.9 - 89.8)	79.5 (76.4 - 82.6)	33.8 (30 - 37.6)	74.8 (64.3 - 85.3)	69.4 (61 - 77.8)
Social functioning	76.5 (61.9 - 91.1)	85.3 (82.9 - 87.7)	86.5(82.9 - 90)	84.4(76.3 - 92.5)	51.3(46.8 - 55.7)	75.9 (63.1 - 88.7)	85.8 (82.1 - 89.5)	59.9 (51.4 - 68.4)	82.5 (79.6 - 85.5)	77.5 (69.1 - 85.9)
<b>Symptom scales</b>										
Fatigue	30.3 (20.5 - 40)	37.4 (22 - 52.9)	19.3 (16.1 - 22.4)	21.8 (19.8 - 23.8)	31.4 (28.5 - 34.3)	24.3 (21.6 - 26.9)	NR	50.3 (43.1 - 57.5)	33.3 (31.5 - 35.1)	43.6 (35.1 - 52)
Nausea and vomiting	13.8 (0 - 31.7)	38.1 (27.3 - 48.9)	13.11 (0 - 37.26)	19.2 (17.3 - 21.2)	14.2 (9 - 19.3)	12.8 (8.3 - 17.3)	NR	40.8 (34.9 - 46.7)	0(0 - 2.1)	30.2 (21.9 - 38.4)
Pain	18.5 (13.9 - 23.1)	34.3 (20.5 - 48)	20.8 (16.1 - 22.4)	9.1 (6.4 - 11.9)	26.3 (20.4 - 32.1)	24 (20.2 - 27.9)	NR	45.1 (41.1 - 49.1)	41.7 (25.3 - 58)	29.4 (21 - 37.9)
Dyspnoea	10.1 (8 - 12.3)	35.1 (17.9 - 52.3)	4.8 (0 - 11.6)	11.2 (7.4 - 15)	4.2 (0.7 - 7.6)	11.1 (9.6 - 12.5)	NR	47 (40.8 - 53.2)	NR	22.5 (13.8 - 31.3)
Insomnia	21.8 (14.8 - 28.8)	41.1 (28.6 - 53.6)	26.1 (15.8 - 36.5)	26 (20 - 32)	30 (23.1 - 36.9)	25.9 (23 - 28.9)	NR	60.5 (51.7 - 69.3)	33.3 (30.4 - 36.2)	42.8 (32.3 - 53.2)
Appetite loss	8.8 (1.9 - 15.8)	37.3 (20.6 - 54.1)	9.4 (5.8 - 13)	12.2 (10.1 - 14.3)	27.5 (20.5 - 34.5)	12.7 (11.5 - 13.9)	NR	44.7 (39.9 - 49.5)	16.6 (0 - 49.2)	24.3 (14.2 - 34.4)
Constipation	11.4 (0.7 - 22.1)	35.6 (15.8 - 55.4)	17.8 (12.9 - 22.6)	17 (14.8 - 19.3)	12.5 (7.4 - 17.6)	16.6 (14.6 - 18.5)	NR	35.5 (31.5 - 39.5)	NR	29.8 (19.9 - 39.6)
Diarrhoea	5.6 (3.7 - 7.6)	35.7 (13.5 - 57.8)	2 (0.5 - 3.6)	9.4 (4.2 - 14.6)	11.7 (6.4 - 16.9)	7 (5.3 - 8.6)	NR	34.9 (31 - 38.8)	NR	18.7 (10.5 - 26.9)
Financial difficulties	15.5 (7.8 - 23.2)	44.3 (12.2 - 76.4)	18.7 (6.4 - 31)	16.1 (22.7 - 11.5)	27.5 (22.3 - 32.7)	31.7 (26.4 - 37)	76.7 (71.4 - 82)	55.3 (45 - 65.6)	16.6 (0 - 49.2)	42.8 (32.4 - 53.2)

QLQ-B23

Table C. Meta-analysis of HRQoL by EORTC QLQ-B23 broken down by country and stage.									
Stage	I-II and III							IV	
Country	Argentina	Brazil	Chile	Colombia	Mexico	Paraguay	Peru	Brazil	Mexico
Studies	2	12	1	1	5	1	1	2	1
N	271	2037	91	362	782	125	38	248	47
Body image	69.1 (50.6 - 87.6)	76.6 (66.3 - 87)	80.5 (75.2 - 85.8)	85.3 (83 - 87.6)	66.6 (43.4 - 89.9)	75.8 (70.7 - 80.9)	44.1 (42.4 - 45.8)	82.5 (73.2 - 91.8)	81.5 (59.8 - 100)
Sexual enjoyment	60.9 (57.3 - 64.5)	50.9 (40.8 - 61.1)	17.3 (14.2 - 20.4)	85.4 (82.5 - 88.3)	34.3 (21.9 - 46.7)	18.2 (12.8 - 23.6)	NR	54.6 (40.3 - 68.8)	21.6 (14.9 - 28.3)
Sexual functioning	42.9 (22.7 - 63.1)	47.4 (32.4 - 62.4)	56.4 (49.2 - 63.6)	84.6 (82.3 - 86.9)	35.6 (19 - 52.2)	14.5 (10.6 - 18.4)	24.1 (22.5 - 25.7)	58.9 (31.9 - 85.9)	11.5 (6.3 - 16.6)
Future perspective	46.1 (11.7 - 80.6)	53.7 (44 - 63.4)	16.9 (13.3 - 20.5)	59.6 (56.7 - 62.5)	53.8 (37.5 - 70.2)	51.5 (46.2 - 56.8)	NR	29.1 (4.6 - 53.6)	44.4 (33.5 - 55.3)
Arm symptoms	22.9 (14.3 - 31.4)	33.4 (26.6 - 40.2)	18.6 (14.7 - 22.5)	21.7 (19 - 24.4)	27.7 (13.8 - 41.6)	80.8 (77 - 84.6)	NR	22.2 (20.6 - 23.8)	23.2 (17 - 29.5)
Breast symptoms	12.9 (9.1 - 16.7)	37.2 (23.9 - 50.5)	18.8 (13.6 - 24)	15.4 (13.5 - 17.3)	27.2 (10.4 - 43.9)	81.9 (79.1 - 84.7)	36.2 (33.2 - 39.2)	16.7 (15.4 - 18)	21.8 (14 - 29.5)
Systemic therapy side effects	28.1 (8.7 - 47.5)	39.4 (27.8 - 51)	18.1 (13.9 - 22.3)	25.7 (23.9 - 27.5)	27.7 (21.8 - 33.7)	75.7 (72.3 - 79.1)	NR	25 (23.6 - 26.4)	30.6 (24.3 - 36.8)
Upset by hair loss	28.3 (21 - 35.6)	63 (49.5 - 76.4)	42 (36.4 - 47.6)	19.9 (16.9 - 22.9)	36.8 (15.6 - 58)	69.9 (63.8 - 76)	NR	NR	29.3 (20.9 - 37.7)

FACT-B

Table D. Meta-analysis of HRQoL by FACT-B broken down by country and stage.						
Country	Stage I – II and III				Stage IV	
	Argentina	Brazil	Mexico	Colombia	Argentina	Colombia

<b>Studies</b>	<b>1</b>	<b>6</b>	<b>1</b>	<b>2</b>	<b>1</b>	<b>1</b>
<b>N</b>	<b>156</b>	<b>591</b>	<b>142</b>	<b>237</b>	<b>20</b>	<b>4</b>
<b>Physical well-being</b>	17 (16.5 - 17.6)	21.5 (20.4 - 22.7)	22.9 (22.2 - 23.6)	20.9 (20.1 - 21.7)	11.2 (8.4 - 14.1)	20.0 (12.6 - 27.3)
<b>Social/family well-being</b>	24.7 (23.9 - 25.5)	19.8 (18.6 - 20.9)	20.5 (19.6 - 21.4)	20.3 (18.1 - 22.5)	8.7 (6.0 - 11.5)	21 (11.4 - 30.6)
<b>Emotional well-being</b>	7.1 (6.5 - 7.7)	18.3 (17.4 - 19.2)	15.7 (14.8 - 16.5)	18.9 (17.5 - 20.3)	10 (7.8 - 12.2)	14.5 (5.4 - 23.6)
<b>Functional well-being</b>	25.7 (25.1 - 26.3)	18.3 (17.7 - 19)	18.1 (17.2 - 19)	19.7 (16.5 - 22.9)	12.5 (9.5 - 15.5)	16.7 (3.9 - 29.4)
<b>Breast cancer subscale</b>	14.2 (13.6 - 14.8)	23.4 (22.4 - 24.5)	23.1 (22.2 - 24)	25.2 (24.3 - 26)	NR	23.7 (13.1 - 34.3)
<b>TOI</b>	40 (39.1 - 40.8)	65.9 (63.6 - 68.3)	64.4 (62.3 - 66.4)	NR	NR	NR
<b>FACT-G</b>	59.9 (58.9 - 60.9)	78.8 (77.4 - 80.2)	77.7 (75.5 - 79.9)	NR	NR	NR
<b>FACT-B total score</b>	74.1 (72.9 - 75.4)	102.1 (98.3 - 105.8)	101.1 (98.2 - 104)	105.7 (93.1 - 118.3)	NR	96 (63.6 - 128.4)



# PRISMA 2009 Checklist

Section/topic	#	Checklist item	Reported on page #
<b>TITLE</b>			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
<b>ABSTRACT</b>			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2
<b>INTRODUCTION</b>			
Rationale	3	Describe the rationale for the review in the context of what is already known.	3,4
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	4
<b>METHODS</b>			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	5
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	5
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	5
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	S1
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	5,6
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	5,6,7
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	6,7

Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	6, S2
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	14-21
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., $I^2$ ) for each meta-analysis.	5,6,7

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	7
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	6,7
<b>RESULTS</b>			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	8
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	8 - 12
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	8
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	13-20
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	14-21
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	13
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	14-21
<b>DISCUSSION</b>			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	21,22
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	24,25

Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	26
<b>FUNDING</b>			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	1

*From:* Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: [www.prisma-statement.org](http://www.prisma-statement.org).